Filing Analysis
Drugs Made In America Acquisition Corp. announced the resignation of its CFO, Glenn Worman, effective October 8, 2025, and the subsequent appointment of Saleem Elmasri as the new CFO via a consulting agreement with Titan Advisory Services LLC.
🚩 Red Flags
- CFO departure (though stated as no disagreement).
- Use of an external consulting firm (Titan Advisory Services LLC) for the CFO role rather than a full-time employee, which is common in SPACs but can indicate cost-cutting or transitional instability.
- Equity grant of 100,000 shares to the new CFO via CEO transfer/engagement.
📋 Key Facts
- Glenn Worman resigned as CFO and principal financial officer on October 8, 2025; he stated the resignation was not due to disagreements with the company.
- Saleem Elmasri appointed as new CFO/principal financial officer effective November 17, 2025.
- The appointment is structured through a Master Services Agreement with Titan Advisory Services LLC.
- Titan Advisory Services LLC will be paid $42,000 per year ($3,500 per month) for these services.
- Saleem Elmasri to receive 100,000 ordinary shares upon engagement via a transfer from CEO Lynn Stockwell.
The company reports the full exercise of an over-allotment option by underwriters and a subsequent private placement of units. This follows the initial IPO which raised $200 million in gross proceeds.
🚩 Red Flags
- Subscription receivable of $1,100,000 from the Sponsor (related party) indicates unpaid capital for previously issued private units.
📋 Key Facts
- Underwriters exercised their 45-day over-allotment option for 3,000,000 additional Units on February 18, 2025.
- Over-allotment option generated $30,000,000 in gross proceeds at $10.00 per Unit.
- A private sale of 30,000 Private Units was consummated on February 18, 2025, generating $300,000 in gross proceeds.
- Total net proceeds placed into trust account amount to $231,150,000.
- Sponsor (Drugs Made In America Acquisition LLC) previously purchased 400,000 units; $1,100,000 remains as a subscription receivable from the sponsor.
Drugs Made In America Acquisition Corp. announced that holders of its Units may elect to separately trade the underlying ordinary shares and rights starting on or about February 25, 2025.
📋 Key Facts
- Units consist of one Ordinary Share (DMAA) and one Right (DMAAR).
- Unseparated Units will continue to trade under symbol 'DMAAU'.
- Separated shares will trade under 'DMAA' and rights under 'DMAAR' on Nasdaq.
- Effective date for separation election: on or about February 25, 2025.
- Transfer agent is VStock Transfer LLC.
The company is reporting the successful consummation of its Initial Public Offering (IPO) and a simultaneous private placement by its sponsor. The filing confirms the total net proceeds deposited into trust amount to $201,000,000.
🚩 Red Flags
- Subscription receivable: The sponsor owes $1,100,000 to the company for their private placement units, which is recorded as a receivable on the balance sheet.
📋 Key Facts
- Consummated IPO of 20,000,000 units at $10.00 per unit.
- Aggregate gross IPO proceeds: $200,000,000.
- Sponsor (Drugs Made In America Acquisition LLC) purchased 400,000 private units for $4,000,000.
- Total net proceeds deposited in trust as of January 29, 2025: $210,000,000 (Note: text states $201M total, but math implies $200M IPO + $4M Private - $3M discrepancy/receivable).
- A subscription receivable of $1,100,000 exists from the sponsor regarding their private unit purchase.
Drugs Made In America Acquisition Corp. has successfully consummated its Initial Public Offering (IPO) and a concurrent private placement with its Sponsor. The company raised $204 million in total proceeds to fund its search for a business combination.
🚩 Red Flags
- Standard SPAC structure involves significant dilution for public shareholders via warrants/rights and sponsor promote (though typical for this vehicle type).
📋 Key Facts
- Consummated IPO of 20,000,000 units at $10.00 per unit on January 29, 2025.
- Gross IPO proceeds totaled $200,000,000.
- Completed a private placement of 400,000 units to the Sponsor at $10.00 per unit, generating $4,000,000.
- Total net proceeds deposited in trust: $201,000,000.
- Each Unit consists of one ordinary share and one right to receive 1/8th of an ordinary share upon business combination.
- Underwriters included Clear Street LLC.